AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03054259
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250ml infusion on days 1 and 15
Trial: NCT02219971
Drug: Kukoamine B Mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Trial: NCT03668314
Drug: RDN-929
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose from 2 mg to TBD
Trial: NCT03668314
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo Single dose
Trial: NCT01150890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as as an intravenous (IV) infusion over at least 30 minutes.
Trial: NCT01804218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03668314
Drug: RDN-929
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose based on results of previous cohorts
Trial: NCT03668314
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo multiple dose
Trial: NCT00186043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02497313
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01046266
Drug: RO5083945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700mg iv weekly
Trial: NCT01362127
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
Trial: NCT03015727
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
Trial: NCT00001576
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00473460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules orally once daily for 5 days every 8 weeks.
Trial: NCT01516307
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
Trial: NCT02182791
Drug: EE/NET
RxNorm normalized name: EE/NETHDRONE (EQV-FEMHRT 1/5) TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00923000
Drug: Nubian with Long dan xie gan tang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
Trial: NCT00249691
Drug: Placebo + Cognitive Behavioral Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day
Trial: NCT01287039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
Trial: NCT01374126
Drug: Azithromycin + Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combination of azithromycin + artesunate
Trial: NCT03840616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once weekly starting on Day 14.
Trial: NCT01327261
Drug: Levodopa + benserazide
RxNorm normalized name: benserazide / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
Trial: NCT00500747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
Trial: NCT01561430
Drug: LY2886721
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01561430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04476719
Drug: ATAFENOVIR 200 MG KAPSUL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 200 mg capsule 0ral administration with 240 ml water
Trial: NCT04476719
Drug: ARBIDOL 100 MG KAPSUL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 100 mg capsules will be administrated with 240 ml water orally.
Trial: NCT03161964
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule over-encapsulated to match propranolol for blinding
Trial: NCT00158600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator; qow for 78 weeks.
Trial: NCT03976583
Drug: Cpp-Acp
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remineralising agent
Trial: NCT03947671
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen will be administered as it would be per standard of care
Trial: NCT01672112
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Codeine 60mg 6hrly/prn
Trial: NCT01327703
Drug: Panzytrat® 25,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
Trial: NCT01327703
Drug: Kreon® 25,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
Trial: NCT01247246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02408068
Drug: Immediate release hydrocortisone: fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 20mg immediate release hydrocortisone in the absence of food
Trial: NCT02408068
Drug: Chronocort: fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 20mg modified release hydrocortisone in the presence of food
Trial: NCT01340768
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
Trial: NCT03069950
Drug: FLUOROURACIL
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
Trial: NCT03069950
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
Trial: NCT02472535
Drug: MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)
Trial: NCT00822341
Drug: TG-0054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion
Trial: NCT01008852
Drug: SBI-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
Trial: NCT01008852
Drug: SBI-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
Trial: NCT01008852
Drug: SBI-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
Trial: NCT01008852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
Trial: NCT00731003
Drug: Oxitriptan
RxNorm normalized name: Oxitriptan
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg 5-Hydroxytryptophan will be administered orally.
Trial: NCT00145275
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00731003
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 5-HTP
Trial: NCT00644449
Drug: azithromycin SR (Zithromax; compound: CP-62,993)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
Trial: NCT03485053
Drug: IOP Injection / MPB-1514
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilute with 5% Dextrose solution (D5W)
Trial: NCT00657228
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.~To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone.
Trial: NCT04145583
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Trial: NCT02996760
Drug: Growth Factor, Platelet-Derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,5 mL, vaginal use , 3 dose number
Trial: NCT00085423
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
Trial: NCT02949934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01844739
Drug: NVN1000 4% Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically twice daily
Trial: NCT01844739
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically twice daily
Trial: NCT03880916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Trial: NCT02390141
Drug: ZP4207
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02390141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01124344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 0 mg, Once Daily, 14 days
Trial: NCT02994940
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: already included in arm/group descriptions
Trial: NCT02141035
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
Trial: NCT02651454
Drug: Daesiho-tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Trial: NCT02651454
Drug: Chowiseungcheng-tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
Trial: NCT02651454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Trial: NCT01321008
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
Trial: NCT01321008
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
Trial: NCT02145312
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
Trial: NCT00395382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly orally
Trial: NCT01321619
Drug: Daflon
RxNorm normalized name: Daflonex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
Trial: NCT04203875
Drug: Orencia® (Abatacept)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
Trial: NCT00026364
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00026364
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00753220
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)
Trial: NCT00613938
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule q4-6 hrs for 3 days
Trial: NCT03909295
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
Trial: NCT00939120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
Trial: NCT01586169
Drug: triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once
Trial: NCT01743131
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04840238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT00649688
Drug: Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/50mg, single dose fasting
Trial: NCT00649688
Drug: Lopressor HCT® Tablets 100/50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/50mg, single dose fasting
Trial: NCT00703573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID
Trial: NCT00248547
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
Trial: NCT01576874
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered intranasally one time
Trial: NCT02701166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 400mg per day
Trial: NCT01629966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
Trial: NCT04393766
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline(crystalloids)
Trial: NCT02981641
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy
Trial: NCT00770536
Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
Trial: NCT01649466
Drug: LAF237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin will be used as commercially available tablets of 50mg.
Trial: NCT03916198
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
Trial: NCT01125748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
Trial: NCT03603704
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03603704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03118570
Drug: zoledronic acid (optional)
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
Trial: NCT03970837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GSK3196165 and Tofacitinib was administered.
Trial: NCT03918109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intratympanic injection of placebo
Trial: NCT01055327
Drug: No anti-epileptic drug exposure
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
Trial: NCT01689662
Drug: Tc 99m EC20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01997229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04014855
Drug: Iron Supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in iron deficiency anemia
Trial: NCT03514797
Drug: Bleaching Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.
Trial: NCT03776838
Drug: Intravenous Fentanyl guided by SoC+NOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
Trial: NCT03776838
Drug: Intravenous Fentanyl guided by SoC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
Trial: NCT03514797
Drug: Bleaching Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
Trial: NCT01303705
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.